As adults aged 1865 years with no known serious chronic diseases were included, the findings may not be generalized to people above 65 years of age or populations with other co-existing comorbidities
Abstract Background In idiopathic intracranial hypertension (IIH), sustained weight loss is the main pillar in modifying disease course, whereby glucagon-like peptide-1 receptor agonists (GLP-1-RAs) could present an attractive treatment option
Semaglutide The SUSTAIN-6 (trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes) was a double-blind trial in which T2D patients were randomized to receive either 0.5 or 1.0 mg of once-weekly subcutaneous semaglutide or placebo (Marso et al., 2016a)
it works mainly by switching on AMPK, the enzyme that regulates metabolism and energy , much closer to how metformin behaves
A new addition to the GLP-1 medication group is retatrutide
20.8% of patients reported using Tirzepatide, 15.3% reported utilizing a combination of multiple drugs